The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Increase In Market Value Is Predicted For The Neurodegenerative Disease Market During The 2026–2030 Period?
The neurodegenerative disease market has experienced robust expansion recently. Projections indicate its value will rise from $57.23 billion in 2025 to $62.59 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. Historically, this growth has been driven by factors such as a restricted comprehension of disease mechanisms, a dependence on traditional symptom-focused therapies, an expanding elderly demographic, improvements in neurological healthcare infrastructure, and the scarce availability of sophisticated diagnostic instruments.
The neurodegenerative disease market is anticipated to show significant expansion in the coming years. It is projected to achieve a size of $88.5 billion by 2030, with a compound annual growth rate (CAGR) of 9.0%. This growth during the forecast period is attributable to advancements in gene and cell therapy, increased research and development into new neuroprotective drugs, the broadening of clinical trial networks, the incorporation of artificial intelligence for prompt diagnosis and patient observation, and a greater uptake of personalized medicine approaches. Noteworthy trends for this period involve the increasing prevalence of neurodegenerative disorders, escalating investment in drug development and clinical trials, the adoption of targeted and individualized therapies, an uptick in awareness and early detection programs, and the expansion of home-based and outpatient care solutions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24618&type=smp
What Key Growth Drivers Are Influencing The Neurodegenerative Disease Market?
The future expansion of the neurodegenerative disease market is anticipated due to a rise in research and clinical trials. Clinical trials are defined as investigative studies involving human subjects that assess the safety, effectiveness, and possible adverse reactions of novel therapies, medications, or medical equipment. The primary impetus behind the surge in research and clinical trials stems from the growing need for innovative treatments to meet changing healthcare demands and enhance patient results. These trials provide essential data on the safety and effectiveness of emerging therapies, thereby aiding neurodegenerative disease research, fostering therapeutic progress, and bettering patient outcomes. As an illustration, a report issued in December 2024 by the Association of the British Pharmaceutical Industry (ABPI), an organization based in the UK, indicated that the initiation of UK industry clinical trials increased by 3.7% in 2023 compared to 2022. Consequently, the neurodegenerative disease market is projected to grow significantly as research and clinical trial activities expand.
How Does Segment Analysis Break Down The Neurodegenerative Disease Market Structure?
The neurodegenerative disease market covered in this report is segmented –
1) By Disease Type: Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis, Huntington Disease, Amyotrophic Lateral Sclerosis
2) By Drug Type: N-methyl-D-aspartate Receptor antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Acetylcholinesterase (AChE) Inhibitors, Antagonist, Monoamine Oxidase B (MAO-B) Inhibitor, Catechol-O-Methyltransferase (COMT) Inhibitor, Selective Serotonin Reuptake Inhibitor (SSRIs), Other Drug Types
3) By Route of Administration: Oral, Injectable, Transdermal, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
5) By End-User: Hospital, Retail, Online
Subsegments:
1) By Parkinson’s Disease: Idiopathic Parkinson’s Disease, Familial Parkinson’s Disease, Early-Onset Parkinson’s Disease, Parkinsonism
2) By Alzheimer’s Disease: Early-Onset Alzheimer’s Disease, Late-Onset Alzheimer’s Disease, Familial Alzheimer’s Disease (FAD), Inflammatory Subtype, Non-Inflammatory Subtype, Cortical Subtype
3) By Multiple Sclerosis (MS): Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS), Progressive-Relapsing MS (PRMS)
4) By Huntington’s Disease: Adult-Onset Huntington’s Disease, Juvenile Huntington’s Disease
5) By Amyotrophic Lateral Sclerosis (ALS): Classical ALS, Limb-Onset ALS, Bulbar-Onset ALS, Respiratory-Onset ALS, Primary Lateral Sclerosis (PLS), Progressive Muscular Atrophy (PMA), Juvenile ALS, ALS-Parkinsonism-Dementia Complex (ALS-PDC)
What Trends Are Impacting The Neurodegenerative Disease Market?
Leading firms in the neurodegenerative disease market are concentrating on creating cutting-edge products, specifically next-generation adaptive Deep Brain Stimulation (aDBS) systems, with the goal of refining treatment accuracy, boosting disease-modifying outcomes, and elevating patients’ quality of life. These next-generation aDBS systems are sophisticated neurostimulation devices designed to offer real-time, customized treatment for Parkinson’s disease. They achieve this by adaptively altering stimulation settings informed by neural feedback, thereby optimizing therapeutic benefits and reducing adverse effects to improve patient results. As an illustration, in February 2025, Medtronic, a medical technology firm based in the US, secured approval from the U.S. Food and Drug Administration (USFDA) for what is recognized as the world’s first adaptive deep brain stimulation (aDBS) system specifically for Parkinson’s disease. This endorsement relates to the premarket approval (PMA) submission for the Percept RC neurostimulator, featuring BrainSense technology, which autonomously adapts therapy based on a patient’s brain signals. The system has undergone clinical validation, demonstrating its ability to alleviate symptoms for individuals with advanced Parkinson’s disease, marking a substantial progression in personalized neuromodulation treatments.
Which Companies Are Influencing The Neurodegenerative Disease Market?
Major companies operating in the neurodegenerative disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Sanofi S.A., Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Biogen Inc., Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics Inc., Voyager Therapeutics Inc., AC Immune SA, Amylyx Pharmaceuticals Inc., Sage Therapeutics Inc., Alzheon Inc.
Access The Complete Neurodegenerative Disease Market Report:
https://www.thebusinessresearchcompany.com/report/neurodegenerative-disease-global-market-report
Which Region Commands The Largest Share Of The Neurodegenerative Disease Market?
North America was the largest region in the neurodegenerative disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurodegenerative disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Neurodegenerative Disease Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24618&type=smp
Browse Through More Reports Similar to the Global Neurodegenerative Disease Market 2026, By The Business Research Company
Rare Neurological Disease Treatment Market Report 2026
Degenerative Disc Disease Treatment Market Report 2026
Neurological Disorder Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model